A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines. / Goksøyr, Louise; Skrzypczak, Magdalena; Sampson, Maureen; Nielsen, Morten A.; Salanti, Ali; Theander, Thor G.; Remaley, Alan T.; Jongh, Willem A. De; Sander, Adam F.

In: Vaccines, Vol. 11, No. 1, 2, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Goksøyr, L, Skrzypczak, M, Sampson, M, Nielsen, MA, Salanti, A, Theander, TG, Remaley, AT, Jongh, WAD & Sander, AF 2023, 'A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines', Vaccines, vol. 11, no. 1, 2. https://doi.org/10.3390/vaccines11010002

APA

Goksøyr, L., Skrzypczak, M., Sampson, M., Nielsen, M. A., Salanti, A., Theander, T. G., Remaley, A. T., Jongh, W. A. D., & Sander, A. F. (2023). A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines. Vaccines, 11(1), [2]. https://doi.org/10.3390/vaccines11010002

Vancouver

Goksøyr L, Skrzypczak M, Sampson M, Nielsen MA, Salanti A, Theander TG et al. A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines. Vaccines. 2023;11(1). 2. https://doi.org/10.3390/vaccines11010002

Author

Goksøyr, Louise ; Skrzypczak, Magdalena ; Sampson, Maureen ; Nielsen, Morten A. ; Salanti, Ali ; Theander, Thor G. ; Remaley, Alan T. ; Jongh, Willem A. De ; Sander, Adam F. / A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines. In: Vaccines. 2023 ; Vol. 11, No. 1.

Bibtex

@article{b3da495a0196411c834cff1a42b00b4c,
title = "A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines",
abstract = "Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation of immune complexes. Here, we utilize a versatile capsid virus-like particle (cVLP)-based vaccine platform to deliver both full-length (FL) PCSK9 and PCSK9-derived peptide antigens, to investigate whether induction of a broader polyclonal anti-PCSK9 antibody response would mediate more efficient clearance of plasma PCSK9. This head-to-head immunization study reveals a significantly increased capacity of the FL PCSK9 cVLP vaccine to opsonize and clear plasma PCSK9. These findings may have implications for the design of PCSK9 and other vaccines that should effectively mediate opsonization and immune clearance of target antigens.",
author = "Louise Goks{\o}yr and Magdalena Skrzypczak and Maureen Sampson and Nielsen, {Morten A.} and Ali Salanti and Theander, {Thor G.} and Remaley, {Alan T.} and Jongh, {Willem A. De} and Sander, {Adam F.}",
year = "2023",
doi = "10.3390/vaccines11010002",
language = "English",
volume = "11",
journal = "Vaccines",
issn = "2076-393X",
publisher = "MDPI AG",
number = "1",

}

RIS

TY - JOUR

T1 - A cVLP-based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines

AU - Goksøyr, Louise

AU - Skrzypczak, Magdalena

AU - Sampson, Maureen

AU - Nielsen, Morten A.

AU - Salanti, Ali

AU - Theander, Thor G.

AU - Remaley, Alan T.

AU - Jongh, Willem A. De

AU - Sander, Adam F.

PY - 2023

Y1 - 2023

N2 - Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation of immune complexes. Here, we utilize a versatile capsid virus-like particle (cVLP)-based vaccine platform to deliver both full-length (FL) PCSK9 and PCSK9-derived peptide antigens, to investigate whether induction of a broader polyclonal anti-PCSK9 antibody response would mediate more efficient clearance of plasma PCSK9. This head-to-head immunization study reveals a significantly increased capacity of the FL PCSK9 cVLP vaccine to opsonize and clear plasma PCSK9. These findings may have implications for the design of PCSK9 and other vaccines that should effectively mediate opsonization and immune clearance of target antigens.

AB - Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation of immune complexes. Here, we utilize a versatile capsid virus-like particle (cVLP)-based vaccine platform to deliver both full-length (FL) PCSK9 and PCSK9-derived peptide antigens, to investigate whether induction of a broader polyclonal anti-PCSK9 antibody response would mediate more efficient clearance of plasma PCSK9. This head-to-head immunization study reveals a significantly increased capacity of the FL PCSK9 cVLP vaccine to opsonize and clear plasma PCSK9. These findings may have implications for the design of PCSK9 and other vaccines that should effectively mediate opsonization and immune clearance of target antigens.

U2 - 10.3390/vaccines11010002

DO - 10.3390/vaccines11010002

M3 - Journal article

C2 - 36679847

VL - 11

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

M1 - 2

ER -

ID: 339995368